FDA warned Belmont Eyecare that its website sells unapproved new drug eye drops with treatment claims.
What happened
In October 2023, FDA reviewed Belmont Eyecare’s website and found six eye drop products offered for sale in the United States. The site claimed the drops treat eye infections, dry eye, cataracts, macular degeneration, and other conditions, and FDA determined the products are unapproved new drugs with no approved application.
What FDA found
The website claims the eye drops treat infections, dry eye, cataracts, macular degeneration, and other conditions, so FDA treats them as drugs.
section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)The products are not generally recognized as safe and effective for those uses, making them new drugs.
section 201(p) of the FD&C Act, 21 U.S.C. 321(p)No FDA-approved application is in effect for any of the six eye drop products.
section 505(a) of the FD&C Act, 21 U.S.C. 355(a)Offering the products for sale in interstate commerce violates the FD&C Act.
sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA asks Belmont Eyecare to notify it in writing within 15 working days of steps taken to correct the violations and prevent recurrence, with supporting documents. If correction cannot be completed in that time, the company must explain the delay and give a completion date.
Who should pay attention
- online sellers of eye drops
- companies making drug-like claims for eye products
- retailers and marketplaces listing similar products
This is a summary. Read the original letter on fda.gov.